Strengths: 50 mg / 12.5 mg and 100 mg / 25 mg
Usage: Management of high blood pressure (hypertension)
Category: Antihypertensive / Cardiovascular Drugs
Therapeutic category: ARB + Thiazide Diuretic
SKU: Losartan Potassium Hydrochlorothiazide Tablets
Categories: Tablets Manufacturer
Losartan Potassium & Hydrochlorothiazide Tablets is listed in our pharmaceutical product portfolio for business-to-business enquiries. Product-specific formulation details, available strengths, dosage form, pack configuration and supply terms should be confirmed against the current product specification before ordering.
For distributor, wholesaler, hospital procurement and export enquiries, please request the applicable product specifications, batch documentation, shelf-life information, packaging options and regulatory documents. Availability and documentation depend on the product and destination market.
Manufactured by: Healthy Life Pharma Pvt. Ltd. (certification subject to verification)
Exported by: Healthy Inc (export credentials subject to verification)
Losartan Potassium and Hydrochlorothiazide is a fixed-dose combination of an angiotensin II receptor blocker (ARB) and a thiazide diuretic for management of hypertension. The medicines act through complementary mechanisms and may help patients whose blood pressure is not adequately controlled with one agent. Healthy Life Pharma Pvt. Ltd. is identified as the manufacturer and Healthy Inc as the exporter; commercial and regulatory credentials should be confirmed before publication.
| Product Name | Losartan Potassium & Hydrochlorothiazide Tablets |
|---|---|
| Composition 1 | Losartan Potassium equivalent to Losartan 50 mg + Hydrochlorothiazide 12.5 mg |
| Composition 2 | Losartan Potassium equivalent to Losartan 100 mg + Hydrochlorothiazide 25 mg |
| Dosage Form | Film-coated tablet (appearance to be confirmed against approved label) |
| Therapeutic Class | Antihypertensive: ARB + Thiazide diuretic |
| Pharmacopoeial standard | USP / BP / IP, as applicable to approved product |
| Shelf life / packaging | Confirm from approved stability data and pack artwork |
| Category | Tablets Manufacturer |
Manufacturing of this combination requires validated blending, content uniformity, moisture control and suitable packaging. Losartan API should be assessed for relevant nitrosamine risks under current regulatory guidance. Specific humidity limits, equipment, nitrosamine results and packaging formats require supporting batch and validation records; they should not be assumed.
Release testing should follow the applicable approved specifications for identity, assay of both active ingredients, content uniformity, dissolution, related substances and microbial quality where relevant. Risk-based nitrosamine evaluation and testing should follow applicable requirements. No specific assay limits, dissolution percentages or impurity-free guarantees are claimed without verified documentation.
Losartan: blocks angiotensin II at AT1 receptors, reducing vasoconstriction and aldosterone effects. Hydrochlorothiazide: increases urinary sodium and water excretion by inhibiting sodium-chloride reabsorption in the distal tubule.
Use: treatment of hypertension when a combination is clinically appropriate. Certain losartan/HCTZ products also have a labeled stroke-risk reduction indication in hypertensive patients with left ventricular hypertrophy; this depends on the jurisdiction and approved labeling. Treatment choice is individualized.
Potential business documentation includes product specifications, Certificate of Analysis, CTD/ACTD dossiers, COPP and Free Sale Certificate, subject to availability and regulatory approval. WHO-GMP status, market authorization, export eligibility, shipment terms and other certificates must be independently verified for the relevant facility and destination.
Q: Why combine losartan and hydrochlorothiazide?
A: They lower blood pressure through complementary mechanisms and may provide better control than either component alone for suitable patients.
Q: Does it increase urination?
A: Hydrochlorothiazide can increase urination, especially after starting treatment.
Q: Is it the same as Hyzaar?
A: Hyzaar is a brand containing these active ingredients. Pharmaceutical equivalence or bioequivalence of a particular manufacturer product must be demonstrated, not assumed.
Q: Is potassium monitoring needed?
A: Yes. Both high and low potassium levels are possible; laboratory monitoring is important.
Use only as prescribed by a qualified clinician. Fixed-dose combinations are commonly taken once daily, but starting strength, dose adjustment and suitability depend on prior treatment, blood pressure response, kidney function and the approved product label. Taking a diuretic earlier in the day may help limit nighttime urination. Do not change the dose independently.
Possible adverse effects include dizziness, low blood pressure, changes in kidney function and electrolyte disturbances (including low sodium and either low or high potassium). Hydrochlorothiazide can increase uric acid, affect blood glucose and cause photosensitivity; it has also been associated with non-melanoma skin cancer risk with cumulative exposure. Pregnancy: drugs acting on the renin–angiotensin system can harm or kill a developing fetus; discontinue promptly under medical direction if pregnancy is detected. Do not use in anuria; review sulfonamide hypersensitivity, kidney/liver disease and interactions. Monitor blood pressure, creatinine and electrolytes.
Store in the original packaging, protected from moisture and excessive heat, according to the approved pack label. The exact temperature limit and shelf life must be taken from validated product-specific stability information. Keep out of reach of children.